Wenxue Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenxue Sun has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Pei Jiang
Translational Pharmaceutical Laboratory, Jining NO.1 People’s Hospital, Shandong First Medical University, Jining, China
5 shared publications Shiyuan Zhao
Translational Pharmaceutical Laboratory Jining NO.1 People's Hospital Shandong First Medical University Jining China
4 shared publicationsJinxiu Guo
Shandong First Med Univ, Jining Peoples Hosp 1, Translat Pharmaceut Lab, Jining 272000, Peoples R China
3 shared publicationsMengmeng Liu
Translational Pharmaceutical Laboratory, Jining First People's Hospital, Shandong First Medical University, Jining 272000, China
3 shared publicationsBeibei Chen
Translational Pharmaceutical Laboratory, Jining First People′s Hospital, Shandong First Medical University, Jining, P.R. China
2 shared publicationsDongxuan Ai
School of Pharmacy and School of Biological and Food Engineering, Changzhou University, Changzhou, Jiangsu 213164, China
2 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Advanced Science
A Novel Bioactive Component, Efoba, From Aged Garlic Targets CTSC to Suppress NET‐Driven Neuroinflammation and Ameliorate Secondary Brain Injury After Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) is a devastating neurological disorder with high mortality and disability, where neuroinflammation‐driven secondary brain injury is a key pathological hallmark. Neutrophil extracellular traps (NETs) serve as critical pathogenic mediators that amplify neuroinflammation, disrupt blood‐brain barrier integrity, and exacerbate brain damage after ICH. This study identifies Efoba, a novel bioactive monomer from aged garlic, and establishes a scalable total‑synthesis route for hundred‑gram‑scale high‑purity production, overcoming low‑yield and supply‑limiting bottlenecks for natural product research. In vivo and in vitro experiments show Efoba markedly ameliorates ICH‑induced neurological impairments and inhibits NET formation. Integrative analyses (Lip‐MS, virtual screening, proteomics, transcriptomics) identified cathepsin C (CTSC) as the direct binding target of Efoba. Efoba stabilizes microglial lysosomal membranes, inhibits CTSC release, blocks NET generation, and exerts neuroprotection against NETs‐driven neuroinflammation. CTSC knockout and CTSC overexpression assays further confirm the indispensable role of CTSC in mediating Efoba's neuroprotective and anti‑inflammatory activities. Collectively, this work demonstrates for the first time that Efoba targets CTSC to suppress NET‐mediated neuroinflammation, highlighting its therapeutic potential and the translational value of natural active components.
- 29 October 2026
- Published by Wiley in Advanced Science
Open AccessA Novel Bioactive Component, Efoba, From Aged Garlic Targets CTSC to Suppress NET‐Driven Neuroinflammation and Ameliorate Secondary Brain Injury After Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) is a devastating neurological disorder with high mortality and disability, where neuroinflammation‐driven secondary brain injury is a key pathological hallmark. Neutrophil extracellular traps (NETs) serve as critical pathogenic mediators that amplify neuroinflammation, disrupt blood‐brain barrier integrity, and exacerbate brain damage after ICH. This study identifies Efoba, a novel bioactive monomer from aged garlic, and establishes a scalable total‑synthesis route for hundred‑gram‑scale high‑purity production, overcoming low‑yield and supply‑limiting bottlenecks for natural product research. In vivo and in vitro experiments show Efoba markedly ameliorates ICH‑induced neurological impairments and inhibits NET formation. Integrative analyses (Lip‐MS, virtual screening, proteomics, transcriptomics) identified cathepsin C (CTSC) as the direct binding target of Efoba. Efoba stabilizes microglial lysosomal membranes, inhibits CTSC release, blocks NET generation, and exerts neuroprotection against NETs‐driven neuroinflammation. CTSC knockout and CTSC overexpression assays further confirm the indispensable role of CTSC in mediating Efoba's neuroprotective and anti‑inflammatory activities. Collectively, this work demonstrates for the first time that Efoba targets CTSC to suppress NET‐mediated neuroinflammation, highlighting its therapeutic potential and the translational value of natural active components.
- 4 November 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 166, 109195
Click-chemistry mediated synthesis of podophyllotoxin triazole ether derivatives: Inhibiting human CRC tumor growth via dual targeting of AKT1 and tubulin
- 4 November 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 166, 109195
Click-chemistry mediated synthesis of podophyllotoxin triazole ether derivatives: Inhibiting human CRC tumor growth via dual targeting of AKT1 and tubulin
- Open Access
- 28 July 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2537345
Therapeutic potential of plant-derived exosome-like nanoparticles for CNS diseases: advancements in preparation and characterization
Background: Central nervous system (CNS) diseases pose significant therapeutic challenges owing to their complex pathophysiology and the restrictive nature of the blood-brain barrier (BBB). Introduction: Plant-derived exosome-like nanoparticles (PDELNs) exhibit intrinsic bioactivity, low immunogenicity, and ability to cross the BBB, making them a promising therapeutic strategy for CNS disorders. Discussion: This review explores the preparation, isolation, and characterization of PDELNs, with a focus on their therapeutic applications in CNS diseases. We also discuss different administration routes and the impact of functional modifications on BBB penetration. Conclusions: PDELNs offer scalability, biocompatibility, and natural pharmacological activity, which make them attractive candidates for CNS drug delivery. However, challenges remain, including standardized isolation, elucidation of BBB penetration mechanisms, and long-term stability and safety. Future research should focus on clarifying their mechanisms of action, optimizing preparation methods, and validating their long-term safety to facilitate the clinical translation of PDELNs. KEY MESSAGESPDELNs are derived from abundant plant sources, exhibit favorable physicochemical properties.PDELNs offer new possibilities for CNS therapies owing to their low immunogenicity, high biocompatibility, and ability to cross the BBB.
- 28 July 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2537345
Open AccessTherapeutic potential of plant-derived exosome-like nanoparticles for CNS diseases: advancements in preparation and characterization
Background: Central nervous system (CNS) diseases pose significant therapeutic challenges owing to their complex pathophysiology and the restrictive nature of the blood-brain barrier (BBB). Introduction: Plant-derived exosome-like nanoparticles (PDELNs) exhibit intrinsic bioactivity, low immunogenicity, and ability to cross the BBB, making them a promising therapeutic strategy for CNS disorders. Discussion: This review explores the preparation, isolation, and characterization of PDELNs, with a focus on their therapeutic applications in CNS diseases. We also discuss different administration routes and the impact of functional modifications on BBB penetration. Conclusions: PDELNs offer scalability, biocompatibility, and natural pharmacological activity, which make them attractive candidates for CNS drug delivery. However, challenges remain, including standardized isolation, elucidation of BBB penetration mechanisms, and long-term stability and safety. Future research should focus on clarifying their mechanisms of action, optimizing preparation methods, and validating their long-term safety to facilitate the clinical translation of PDELNs. KEY MESSAGESPDELNs are derived from abundant plant sources, exhibit favorable physicochemical properties.PDELNs offer new possibilities for CNS therapies owing to their low immunogenicity, high biocompatibility, and ability to cross the BBB.
- Open Access
- 25 September 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 734, 150739
Oct-B: A derivative of L-BAIBA significantly alleviating high-fat diet-induced obesity in mice
- 25 September 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 734, 150739
Open AccessOct-B: A derivative of L-BAIBA significantly alleviating high-fat diet-induced obesity in mice
- 13 June 2024
- Published by Elsevier in Dyes and Pigments
- Vol. 230
A cytoplasm-applicative aggregation-induced fluorescent probe for detecting hydrogen sulfide and imaging study
- 13 June 2024
- Published by Elsevier in Dyes and Pigments
- Vol. 230
A cytoplasm-applicative aggregation-induced fluorescent probe for detecting hydrogen sulfide and imaging study
- Open Access
- 7 March 2024
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 11, 1332090
A GC–MS-based untargeted metabolomics approach for comprehensive metabolic profiling of mycophenolate mofetil-induced toxicity in mice
Background: Mycophenolate mofetil (MMF), the morpholinoethyl ester of mycophenolic acid, is widely used for maintenance immunosuppression in transplantation. The gastrointestinal toxicity of MMF has been widely uncovered. However, the comprehensive metabolic analysis of MMF-induced toxicity is lacking. This study is aimed to ascertain the metabolic changes after MMF administration in mice.Methods: A total of 700 mg MMF was dissolved in 7 mL dimethyl sulfoxide (DMSO), and then 0.5 mL of mixture was diluted with 4.5 mL of saline (100 mg/kg). Mice in the treatment group (n = 9) were given MMF (0.1 mL/10 g) each day via intraperitoneal injection lasting for 2 weeks, while those in the control group (n = 9) received the same amount of blank solvent (DMSO: saline = 1:9). Gas chromatography-mass spectrometry was utilized to identify the metabolic profiling in serum samples and multiple organ tissues of mice. The potential metabolites were identified using orthogonal partial least squares discrimination analysis. Meanwhile, we used the MetaboAnalyst 5.0 (http://www.metaboanalyst.ca) and Kyoto Encyclopedia of Genes and Genomes database (http://www.kegg.jp) to depict the metabolic pathways. The percentages of lymphocytes in spleens were assessed by multiparameter flow cytometry analysis.Results: Compared to the control group, we observed that MMF treatment induced differential expression of metabolites in the intestine, hippocampus, lung, liver, kidney, heart, serum, and cortex tissues. Subsequently, we demonstrated that multiple amino acids metabolism and fatty acids biosynthesis were disrupted following MMF treatment. Additionally, MMF challenge dramatically increased CD4+ T cell percentages but had no significant influences on other types of lymphocytes.Conclusion: MMF can affect the metabolism in various organs and serum in mice. These data may provide preliminary judgement for MMF-induced toxicity and understand the metabolic mechanism of MMF more comprehensively.
- 7 March 2024
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 11, 1332090
Open AccessA GC–MS-based untargeted metabolomics approach for comprehensive metabolic profiling of mycophenolate mofetil-induced toxicity in mice
Background: Mycophenolate mofetil (MMF), the morpholinoethyl ester of mycophenolic acid, is widely used for maintenance immunosuppression in transplantation. The gastrointestinal toxicity of MMF has been widely uncovered. However, the comprehensive metabolic analysis of MMF-induced toxicity is lacking. This study is aimed to ascertain the metabolic changes after MMF administration in mice.Methods: A total of 700 mg MMF was dissolved in 7 mL dimethyl sulfoxide (DMSO), and then 0.5 mL of mixture was diluted with 4.5 mL of saline (100 mg/kg). Mice in the treatment group (n = 9) were given MMF (0.1 mL/10 g) each day via intraperitoneal injection lasting for 2 weeks, while those in the control group (n = 9) received the same amount of blank solvent (DMSO: saline = 1:9). Gas chromatography-mass spectrometry was utilized to identify the metabolic profiling in serum samples and multiple organ tissues of mice. The potential metabolites were identified using orthogonal partial least squares discrimination analysis. Meanwhile, we used the MetaboAnalyst 5.0 (http://www.metaboanalyst.ca) and Kyoto Encyclopedia of Genes and Genomes database (http://www.kegg.jp) to depict the metabolic pathways. The percentages of lymphocytes in spleens were assessed by multiparameter flow cytometry analysis.Results: Compared to the control group, we observed that MMF treatment induced differential expression of metabolites in the intestine, hippocampus, lung, liver, kidney, heart, serum, and cortex tissues. Subsequently, we demonstrated that multiple amino acids metabolism and fatty acids biosynthesis were disrupted following MMF treatment. Additionally, MMF challenge dramatically increased CD4+ T cell percentages but had no significant influences on other types of lymphocytes.Conclusion: MMF can affect the metabolism in various organs and serum in mice. These data may provide preliminary judgement for MMF-induced toxicity and understand the metabolic mechanism of MMF more comprehensively.
- Open Access
- 23 February 2024
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 62 (1) , 233-249
Design, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents
ContextPodophyllotoxin (PPT) derivatives, used in cancer therapy, require development toward enhanced efficacy and reduced toxicity.ObjectiveThis study synthesizes PPT derivatives to assess their anticancer activities.Materials and methodsCompounds E1-E16 antiproliferative activity was tested against four human cancer cell lines (H446, MCF-7, HeLa, A549) and two normal cell lines (L02, BEAS-2B) using the CCK-8 assay. The effects of compound E5 on A549 cell growth were evaluated through molecular docking, in vitro assays (flow cytometry, wound healing, Transwell, colony formation, Western blot), and in vivo tests in female BALB/c nude mice treated with E5 (2 and 4 mg/kg). E5 (4 mg/kg) significantly reduced xenograft tumor growth compared to the DMSO control group.ResultsAmong the 16 PPT derivatives tested for cytotoxicity, E5 exhibited potent effects against A549 cells (IC50: 0.35 +/- 0.13 mu M) and exceeded the reference drugs PPT and etoposide to inhibit the growth of xenograft tumours. E5-induced cell cycle arrest in the S and G2/M phases accelerated tubulin depolymerization and triggered apoptosis and mitochondrial depolarization while regulating the expression of apoptosis-related proteins and effectively inhibited cell migration and invasion, suggesting a potential to limit metastasis. Molecular docking showed binding of E5 to tubulin at the colchicine site and to Akt, with a consequent down-regulation of PI3K/Akt pathway proteins.Discussion and conclusionsThis research lays the groundwork for advancing cancer treatment through developing and using PPT derivatives. The encouraging results associated with E5 call for extended research and clinical validation, leading to novel and more effective cancer therapies.
- 23 February 2024
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 62 (1) , 233-249
Open AccessDesign, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents
ContextPodophyllotoxin (PPT) derivatives, used in cancer therapy, require development toward enhanced efficacy and reduced toxicity.ObjectiveThis study synthesizes PPT derivatives to assess their anticancer activities.Materials and methodsCompounds E1-E16 antiproliferative activity was tested against four human cancer cell lines (H446, MCF-7, HeLa, A549) and two normal cell lines (L02, BEAS-2B) using the CCK-8 assay. The effects of compound E5 on A549 cell growth were evaluated through molecular docking, in vitro assays (flow cytometry, wound healing, Transwell, colony formation, Western blot), and in vivo tests in female BALB/c nude mice treated with E5 (2 and 4 mg/kg). E5 (4 mg/kg) significantly reduced xenograft tumor growth compared to the DMSO control group.ResultsAmong the 16 PPT derivatives tested for cytotoxicity, E5 exhibited potent effects against A549 cells (IC50: 0.35 +/- 0.13 mu M) and exceeded the reference drugs PPT and etoposide to inhibit the growth of xenograft tumours. E5-induced cell cycle arrest in the S and G2/M phases accelerated tubulin depolymerization and triggered apoptosis and mitochondrial depolarization while regulating the expression of apoptosis-related proteins and effectively inhibited cell migration and invasion, suggesting a potential to limit metastasis. Molecular docking showed binding of E5 to tubulin at the colchicine site and to Akt, with a consequent down-regulation of PI3K/Akt pathway proteins.Discussion and conclusionsThis research lays the groundwork for advancing cancer treatment through developing and using PPT derivatives. The encouraging results associated with E5 call for extended research and clinical validation, leading to novel and more effective cancer therapies.
- Open Access
- 5 August 2023
- Published by Wiley in Journal of Toxicology
- Vol. 2023, 1-13
Paclitaxel Induces Neurotoxicity by Disrupting Tricarboxylic Acid Cycle Metabolic Balance in the Mouse Hippocampus
Objective. It is well known that paclitaxel (PTX)-induced neurotoxicity seriously affects the quality of life of patients and is the main reason for reducing the dose of chemotherapy or even stopping chemotherapy. The current data are limited, and further information is required for practice and verification. The aims of this study were to clarify the molecular mechanism underlying PTX-induced neurotoxicity by combining in vivo and in vitro metabolomics studies and provide new targets for the prevention and treatment of PTX-induced neurotoxicity. Methods. In the in vivo study, a PTX-induced neurotoxicity mouse model was established by intraperitoneal injection of PTX (6 mg/kg every three days) for two consecutive weeks. After verification by water maze tests and HE staining of pathological sections, hippocampal metabolites were measured and the differential metabolites and related metabolic pathways were identified by multivariate statistical analysis. In the in vitro study, we investigated the effects of PTX on mouse hippocampal neuron cells, assessing the concentration and time of administration by MTT assays. After modeling, the relevant metabolites in the TCA cycle were quantified by targeted metabolomics using stable isotope labeling. Finally, the key enzymes of the TCA cycle in tissues and cells were verified by RT-PCR. Results. Administration of PTX to model mice resulted in neurological damage, shown by both water-maze tests and hippocampal tissue sections. Twenty-four metabolites and five associated metabolic pathways were found to differ significantly between the hippocampal tissues of the model and control groups. These included metabolites and pathways related to the TCA cycle and pyruvate metabolism. Metabolomics analysis using stable isotope labeling showed significant changes in metabolites associated with the TCA cycle compared with the control group ( ). Finally, RT-PCR verified that the expression of key enzymes in the TCA cycle was changed to different degrees in both hippocampal tissues and cells. Conclusion. Our results showed that PTX neurotoxicity in hippocampal tissue and neuron cells was associated with inhibition of the TCA cycle. This inhibition leads to brain insufficiency and impaired metabolism, resulting in various neurotoxic symptoms.
- 5 August 2023
- Published by Wiley in Journal of Toxicology
- Vol. 2023, 1-13
Open AccessPaclitaxel Induces Neurotoxicity by Disrupting Tricarboxylic Acid Cycle Metabolic Balance in the Mouse Hippocampus
Objective. It is well known that paclitaxel (PTX)-induced neurotoxicity seriously affects the quality of life of patients and is the main reason for reducing the dose of chemotherapy or even stopping chemotherapy. The current data are limited, and further information is required for practice and verification. The aims of this study were to clarify the molecular mechanism underlying PTX-induced neurotoxicity by combining in vivo and in vitro metabolomics studies and provide new targets for the prevention and treatment of PTX-induced neurotoxicity. Methods. In the in vivo study, a PTX-induced neurotoxicity mouse model was established by intraperitoneal injection of PTX (6 mg/kg every three days) for two consecutive weeks. After verification by water maze tests and HE staining of pathological sections, hippocampal metabolites were measured and the differential metabolites and related metabolic pathways were identified by multivariate statistical analysis. In the in vitro study, we investigated the effects of PTX on mouse hippocampal neuron cells, assessing the concentration and time of administration by MTT assays. After modeling, the relevant metabolites in the TCA cycle were quantified by targeted metabolomics using stable isotope labeling. Finally, the key enzymes of the TCA cycle in tissues and cells were verified by RT-PCR. Results. Administration of PTX to model mice resulted in neurological damage, shown by both water-maze tests and hippocampal tissue sections. Twenty-four metabolites and five associated metabolic pathways were found to differ significantly between the hippocampal tissues of the model and control groups. These included metabolites and pathways related to the TCA cycle and pyruvate metabolism. Metabolomics analysis using stable isotope labeling showed significant changes in metabolites associated with the TCA cycle compared with the control group ( ). Finally, RT-PCR verified that the expression of key enzymes in the TCA cycle was changed to different degrees in both hippocampal tissues and cells. Conclusion. Our results showed that PTX neurotoxicity in hippocampal tissue and neuron cells was associated with inhibition of the TCA cycle. This inhibition leads to brain insufficiency and impaired metabolism, resulting in various neurotoxic symptoms.
- Open Access
- 18 January 2022
- Published by Wiley in Journal of Chemistry
- Vol. 2022, 1-12
Research Advances in Antitumor Mechanism of Evodiamine
Evodiamine is a natural alkaloid extracted from Fructus Evodia. This bioactive alkaloid has been reported to have a wide range of biological activities, including anti-injury, antiobesity, vasodilator, and anti-inflammatory effects. In recent years, it has been found that evodiamine has tumor-suppressive effects on a variety of tumors. There is growing evidence that evodiamine can inhibit the rapid proliferation of tumor cells, induce cell cycle arrest at a certain phase, increase the incidence of apoptosis, promote autophagy, inhibit microangiogenesis and migration, and regulate immunotherapy. Evodiamine can inhibit Wnt/β-catenin, mTOR, NF-κB, PI3K/AKT, JAK-STAT, and other signaling pathways in various cancer cells, and it can significantly downregulate the expression of many tumor markers, such as VEGF and COX-2. These facts partially explain the antitumor mechanism of evodiamine. In this article, the antitumor mechanism of evodiamine was reviewed to provide the basis for its clinical application and therapeutic development in the future.
- 18 January 2022
- Published by Wiley in Journal of Chemistry
- Vol. 2022, 1-12
Open AccessResearch Advances in Antitumor Mechanism of Evodiamine
Evodiamine is a natural alkaloid extracted from Fructus Evodia. This bioactive alkaloid has been reported to have a wide range of biological activities, including anti-injury, antiobesity, vasodilator, and anti-inflammatory effects. In recent years, it has been found that evodiamine has tumor-suppressive effects on a variety of tumors. There is growing evidence that evodiamine can inhibit the rapid proliferation of tumor cells, induce cell cycle arrest at a certain phase, increase the incidence of apoptosis, promote autophagy, inhibit microangiogenesis and migration, and regulate immunotherapy. Evodiamine can inhibit Wnt/β-catenin, mTOR, NF-κB, PI3K/AKT, JAK-STAT, and other signaling pathways in various cancer cells, and it can significantly downregulate the expression of many tumor markers, such as VEGF and COX-2. These facts partially explain the antitumor mechanism of evodiamine. In this article, the antitumor mechanism of evodiamine was reviewed to provide the basis for its clinical application and therapeutic development in the future.